Prostate cancer Q&A: Improving detection and reducing overtreatment
Medical Xpress October 8, 2024
Prostate cancer is the most common cancer among men in Sweden, with about 10,000 new cases diagnosed annually. Despite advancements in diagnostics and treatments, managing prostate cancer remains challenging due to its often silent progression and the complexities surrounding early detection.
The Prostate-Specific Antigen (PSA) test, while widely used, has limitations in distinguishing between aggressive and indolent cancers and benign conditions, leading to potential overdiagnosis and overtreatment.
In his thesis, Lars Björnebo, MD and Ph.D. student at the Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, investigated and compared new tools for prostate cancer detection, such as MRI-based diagnostics and the Stockholm3 test, potentially offering hope for more accurate diagnoses. However, ensuring access to these innovations and balancing timely intervention...